Download PDF
Indian Journal of Neurosurgery 2016; 05(02): 084-088
DOI: 10.1055/s-0036-1584591
Original Article
Thieme Medical and Scientific Publishers Private Ltd.

Reduction in Cutis Verticis Gyrata after Transsphenoidal Pituitary Resection of Growth Hormone–Secreting Adenoma

Daniel Pinggera
1   Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria
,
Delia Anna Marsoner
1   Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria
,
Marcel Seiz-Rosenhagen
2   Department of Neurosurgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany
,
Claudius Thomé
1   Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria
,
Christian Franz Freyschlag
1   Department of Neurosurgery, Medical University Innsbruck, Innsbruck, Austria
› Author Affiliations
Further Information

Publication History

26 December 2015

03 February 2016

Publication Date:
19 July 2016 (online)

   Permissions and Reprints

Abstract

Aim Cutis verticis gyrata (CVG) describes a hypertrophy and folding of the skin that appears as gyration of the scalp. Secondary CVG is a common symptom of growth hormone (GH)–producing adenoma of the pituitary and an early sign of acromegaly. We hypothesized that surgical removal of a pituitary adenoma with a consecutive decrease in hormone levels will cause a reduction in gyration.

Methods Imaging and laboratory examination of 10 patients (median age: 44 years) with GH-producing adenoma have been evaluated retrospectively. Surgical treatment consisted of endonasal transsphenoidal resection of the adenoma, followed by endocrinologic and radiographic follow-up. CVG was calculated as area under the curve of the scalp on preoperative coronal T1-weighted MRI, compared with postoperative follow-up imaging after 12 months (AUC, measured in cm2). In laboratory examination, the levels of insulin-like growth factor-1 (IGF-1) were analyzed accordingly as its levels are constant throughout the day.

Results After 12 months, we found a statistically significant (p = 0.008) correlation between the decrease in IGF-1 levels (median: 219.00 ng/mL) and the reduction in CVG (median: 0.12 cm2).

Conclusion Resection of GH-producing pituitary adenoma leads to a decrease in CVG in patients suffering from acromegaly, which is strongly related to the levels of IGF-1

Keywords

acromegaly - cutis verticis gyrate - pituitary adenoma
 

  • References

  • 1 Ostrom QT, Gittleman H, Farah P , et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro-oncol 2013; 15 (Suppl. 02) ii1-ii56
    PubMedGoogle Scholar
  • 2 Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355 (24) 2558-2573
    CrossrefPubMedGoogle Scholar
  • 3 Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2 (1) 29-41
    CrossrefPubMedGoogle Scholar
  • 4 Katznelson L. AACE acromegaly guidelines. Endocr Pract 2011; 17 (Suppl. 04)
    PubMedGoogle Scholar
  • 5 Melmed S, Colao A, Barkan A , et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94 (5) 1509-1517
    CrossrefPubMedGoogle Scholar
  • 6 Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure.”. Eur J Endocrinol 2005; 152 (3) 379-387
    CrossrefPubMedGoogle Scholar
  • 7 Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008; 159 (2) 89-95
    CrossrefPubMedGoogle Scholar
  • 8 Centurión SA, Schwartz RA. Cutaneous signs of acromegaly. Int J Dermatol 2002; 41 (10) 631-634
    CrossrefPubMedGoogle Scholar
  • 9 El-Husseiny MYJ, Moiemen N. Primary cutis gyrata: review of literature and a successful new surgical approach. Eur J Plast Surg 2010; 33 (3) 153-157
    CrossrefPubMedGoogle Scholar
  • 10 Unna P. Cutis gyrata cutis. Monatschr Prakt Derm 1907; 45: 227-233
    PubMedGoogle Scholar
  • 11 Chang GY. Cutis verticis gyrata, underrecognized neurocutaneous syndrome. Neurology 1996; 47 (2) 573-575
    CrossrefPubMedGoogle Scholar
  • 12 Yang JJ, Sano DT, Martins SR, Tebcherani AJ, Sanchez AP. Primary essential cutis verticis gyrata—case report. An Bras Dermatol 2014; 89 (2) 326-328
    CrossrefPubMedGoogle Scholar
  • 13 Guitelman M, Abreu A, Espinosa-de-los-Monteros AL, Mercado M. Patient-focussed outcomes in acromegaly. Pituitary 2014; 17 (Suppl. 01) S18-S23
    CrossrefPubMedGoogle Scholar
  • 14 Kolawole TM, Al Orainy IA, Patel PJ, Fathuddin S. Cutis verticis gyrata: its computed tomographic demonstration in acromegaly. Eur J Radiol 1998; 27 (2) 145-148
    CrossrefPubMedGoogle Scholar
  • 15 Alorainy IA. Magnetic resonance imaging of cutis verticis gyrata. J Comput Assist Tomogr 2008; 32 (1) 119-123
    CrossrefPubMedGoogle Scholar
  • 16 Okamoto K, Ito J, Tokiguchi S, Ishikawa K, Furusawa T, Sakai K. MRI in essential primary cutis verticis gyrata. Neuroradiology 2001; 43 (10) 841-844
    CrossrefPubMedGoogle Scholar
  • 17 Schöfl C, Franz H, Grussendorf M , et al; participants of the German Acromegaly Register. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol 2013; 168 (1) 39-47
    PubMedGoogle Scholar
  • 18 Zeinalizadeh M, Habibi Z, Fernandez-Miranda JC, Gardner PA, Hodak SP, Challinor SM. Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management. Pituitary 2015; 18 (1) 48-59
    CrossrefPubMedGoogle Scholar
  • 19 Dahbar M, Danilowicz K, Malavela M , et al. Cutaneous manifestations of acromegaly. Dermatol Argent 2009; 15: 186-190
    PubMedGoogle Scholar
  • 20 Ben-Shlomo A, Melmed S. Skin manifestations in acromegaly. Clin Dermatol 2006; 24 (4) 256-259
    CrossrefPubMedGoogle Scholar